DelveInsight’s “Atherosclerotic cardiovascular disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Atherosclerotic cardiovascular disease, historical and forecasted epidemiology as well as the Atherosclerotic cardiovascular disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Atherosclerotic cardiovascular disease market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

To Know in detail about the Atherosclerotic cardiovascular disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Atherosclerotic cardiovascular disease Market Insights

Atherosclerotic cardiovascular disease Overview

Atherosclerotic cardiovascular disease, also called “atherosclerosis,” occurs when fatty deposits build up in the arteries. Arteries carry blood and oxygen from the heart to the rest of the body. All organs in the body need this flow of oxygenated blood in order to work.

Some of the key facts of the Atherosclerotic cardiovascular disease Market Report: 

• The Atherosclerotic cardiovascular disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• According to Vasan et al. (2022), In the United States, ASCVD afflicts about 26 million people, and results in 2 million hospitalizations and 400,000 deaths every year. Therefore, preventing Atherosclerotic cardiovascular disease via effective risk assessment, communication, and management is a public health priority
• In August 2022,  AstraZeneca and Merck, known as MSD outside the United States and Canada, announced that the European Commission (EC) has approved LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations (gBRCAm) and HER2-negative high-risk early breast cancer who have previously received neoadjuvant or adjuvant chemotherapy
• In July 2022, GSK plc announced that its wholly owned subsidiary, GSK Finance (No.3) plc, will repurchase all of its outstanding Exchangeable Senior Notes due 2023 for cash
• As per retrospective analysis was conducted using the Japan Medical Data Center (JMDC) database (2006–2011), Atherosclerotic cardiovascular disease prevalence in Japan was 1,869/100,000 population
• According to Zardawi et al. (2020), Atherosclerotic cardiovascular disease in Europe is responsible for approximately 3.9 million deaths (45% of deaths) annually
• Key Atherosclerotic cardiovascular disease Companies: Silence Therapeutics, Ionis Pharmaceuticals, Amgen, GlaxoSmithKline Plc., Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Isis, Pharmaceuticals, Inc., Anthera Pharmaceuticals, Novartis AG, Sanofi, Johnson and Johnson, Bayer AG, The Medicine Company and Cardium Therapeutics, and others
• Key Atherosclerotic cardiovascular disease Therapies: SLN360, Olezarsen, Olpasiran, and others
• The Atherosclerotic cardiovascular disease epidemiology based on gender analyzed that Atherosclerotic cardiovascular diseases are considered as the leading cause of mortality among women due to gender-specific risk factors such as menarche, menopause, parity, and pregnancy-related diseases, and approximately 40% of them have a lifetime risk of developing ASCVDs after age 50 years

Get a Free sample for the Atherosclerotic cardiovascular disease Market Report – 

https://www.delveinsight.com/sample-request/atherosclerotic-cardiovascular-disease-ascvd-market

Key benefits of the Atherosclerotic cardiovascular disease Market report:

1. Atherosclerotic cardiovascular disease market report covers a descriptive overview and comprehensive insight of the Atherosclerotic cardiovascular disease Epidemiology and Atherosclerotic cardiovascular disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Atherosclerotic cardiovascular disease market report provides insights on the current and emerging therapies.
3. Atherosclerotic cardiovascular disease market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Atherosclerotic cardiovascular disease market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Atherosclerotic cardiovascular disease market.

Download the report to understand which factors are driving Atherosclerotic cardiovascular disease epidemiology trends @ Atherosclerotic cardiovascular disease Epidemiological Insights 

Atherosclerotic cardiovascular disease Market  

The dynamics of the Atherosclerotic cardiovascular disease market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

“In December 2021, the US FDA approved Novartis Pharmaceuticals’ LEQVIO (inclisiran), a small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol (LDL-C), which is among the most readily modifiable risk factors for ASCVD with two doses a year, after an initial dose and one at three months.”

Atherosclerotic cardiovascular disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Atherosclerotic cardiovascular disease Epidemiology Segmentation:

The Atherosclerotic cardiovascular disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Atherosclerotic cardiovascular disease
• Prevalent Cases of Atherosclerotic cardiovascular disease by severity
• Gender-specific Prevalence of Atherosclerotic cardiovascular disease
• Diagnosed Cases of Episodic and Chronic Atherosclerotic cardiovascular disease

Atherosclerotic cardiovascular disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Atherosclerotic cardiovascular disease market or expected to get launched during the study period. The analysis covers Atherosclerotic cardiovascular disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Atherosclerotic cardiovascular disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Discover more about therapies set to grab major Atherosclerotic cardiovascular disease market share @ Atherosclerotic cardiovascular disease market forecast 

Atherosclerotic cardiovascular disease Therapies and Key Companies

• SLN360: Silence Therapeutics
• Olezarsen: Ionis Pharmaceuticals
• Olpasiran: Amgen

Atherosclerotic cardiovascular disease Market Strengths

• The pathophysiology of the disease is well understood
• In the coming years, the incidence of this disease might increase

Scope of the Atherosclerotic cardiovascular disease Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Atherosclerotic cardiovascular disease Companies: Silence Therapeutics, Ionis Pharmaceuticals, Amgen, GlaxoSmithKline Plc., Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Isis, Pharmaceuticals, Inc., Anthera Pharmaceuticals, Novartis AG, Sanofi, Johnson and Johnson, Bayer AG, The Medicine Company and Cardium Therapeutics, and others
• Key Atherosclerotic cardiovascular disease Therapies: SLN360, Olezarsen, Olpasiran, and others
• Atherosclerotic cardiovascular disease Therapeutic Assessment: Atherosclerotic cardiovascular disease current marketed and Atherosclerotic cardiovascular disease emerging therapies
• Atherosclerotic cardiovascular disease Market Dynamics: Atherosclerotic cardiovascular disease market drivers and Atherosclerotic cardiovascular disease market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Atherosclerotic cardiovascular disease Unmet Needs, KOL’s views, Analyst’s views, Atherosclerotic cardiovascular disease Market Access and Reimbursement 

Atherosclerotic cardiovascular disease Market Unmet Needs

• Challenges in diagnosis
• Development of novel therapies
• Quality of life
• Socio-economic burden

Table of Contents 

1. Atherosclerotic cardiovascular disease Market Report Introduction

2. Executive Summary for Atherosclerotic cardiovascular disease

3. SWOT analysis of Atherosclerotic cardiovascular disease

4. Atherosclerotic cardiovascular disease Patient Share (%) Overview at a Glance

5. Atherosclerotic cardiovascular disease Market Overview at a Glance

6. Atherosclerotic cardiovascular disease Disease Background and Overview

7. Atherosclerotic cardiovascular disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Atherosclerotic cardiovascular disease 

9. Atherosclerotic cardiovascular disease Current Treatment and Medical Practices

10. Atherosclerotic cardiovascular disease Unmet Needs

11. Atherosclerotic cardiovascular disease Emerging Therapies

12. Atherosclerotic cardiovascular disease Market Outlook

13. Country-Wise Atherosclerotic cardiovascular disease Market Analysis (2019–2032)

14. Atherosclerotic cardiovascular disease Market Access and Reimbursement of Therapies

15. Atherosclerotic cardiovascular disease Market Drivers

16. Atherosclerotic cardiovascular disease Market Barriers

17.  Atherosclerotic cardiovascular disease Appendix

18. Atherosclerotic cardiovascular disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

To know more about Atherosclerotic cardiovascular disease treatment, visit @ Atherosclerotic cardiovascular disease Medications

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services